Bristol Myers Squibb Company $BMY Shares Acquired by Corient Private Wealth LP

Corient Private Wealth LP lifted its holdings in Bristol Myers Squibb Company (NYSE:BMY - Free Report) by 19.5% during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 532,609 shares of the biopharmaceutical company's stock after buying an additional 86,788 shares during the quarter. Corient Private Wealth LP's holdings in Bristol Myers Squibb were worth $30,689,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently bought and sold shares of BMY. California State Teachers Retirement System increased its holdings in shares of Bristol Myers Squibb by 5,484.7% in the 2nd quarter. California State Teachers Retirement System now owns 185,255,963 shares of the biopharmaceutical company's stock valued at $10,674,449,000 after purchasing an additional 181,938,762 shares in the last quarter. Norges Bank purchased a new stake in Bristol Myers Squibb during the fourth quarter worth about $1,947,272,000. Primecap Management Co. CA purchased a new stake in Bristol Myers Squibb during the second quarter worth about $1,436,115,000. Legal & General Group Plc acquired a new position in Bristol Myers Squibb during the second quarter worth about $980,862,000. Finally, AQR Capital Management LLC increased its holdings in Bristol Myers Squibb by 172.6% in the fourth quarter. AQR Capital Management LLC now owns 25,796,905 shares of the biopharmaceutical company's stock valued at $1,391,485,000 after buying an additional 16,332,924 shares in the last quarter. Institutional investors and hedge funds own 76.41% of the company's stock.

More Bristol Myers Squibb News

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: Promising multiple myeloma CAR-T results strengthen the pipeline. Bristol Myers said experimental therapy arlocabtagene autoleucel (arlo-cel) met the primary goal of a mid-stage trial in heavily pretreated multiple myeloma patients. The statistically significant and clinically meaningful improvement in overall response rate could support the company’s long-term oncology growth prospects. Bristol Myers’ Cancer Therapy Win Strengthens its Oncology Pipeline
• Positive Sentiment: Growth brands and pipeline progress remain supportive. An analyst review noted that Bristol Myers’ newer growth products and research pipeline are helping drive momentum, contributing to a reported 19.4% year-to-date gain before the latest weakness. BMY Gains 19.4% Year to Date: Should You Buy, Sell or Hold the Stock?
• Neutral Sentiment: Analyst stance remains cautious. Scotiabank maintained a Hold rating, suggesting the positive pipeline developments are not yet sufficient to prompt a more bullish view.
• Neutral Sentiment: Long-term psoriasis study data add information but not an immediate catalyst. Bristol Myers provided an update on an ongoing long-term psoriasis study; the available report did not identify a major change to near-term earnings expectations. Bristol-Myers Squibb’s Long-Term Psoriasis Study Brings Fresh Data for BMY Investors
• Negative Sentiment: Patent-dispute uncertainty weighs on sentiment. RBC said Cytokinetics has an advantage in its patent dispute with Bristol Myers, raising potential legal and competitive concerns. Cytokinetics Has Advantage in Bristol-Myers Squibb Patent Dispute, RBC Says
• Negative Sentiment: Downside hedging and portfolio pressure are visible. Investors purchased about 44,454 BMY put options, roughly 71% above average put volume. Analysts also continue to flag generic pressure on the legacy portfolio, while the stock recently underperformed the broader market.

Bristol Myers Squibb Trading Down 0.2%

Shares of BMY opened at $63.52 on Monday. Bristol Myers Squibb Company has a 1-year low of $42.52 and a 1-year high of $68.64. The company has a debt-to-equity ratio of 1.89, a current ratio of 1.53 and a quick ratio of 1.38. The firm has a 50 day simple moving average of $63.61 and a 200-day simple moving average of $60.07. The stock has a market cap of $129.76 billion, a price-to-earnings ratio of 13.99, a price-to-earnings-growth ratio of 0.30 and a beta of 0.23.

Bristol Myers Squibb (NYSE:BMY - Get Free Report) last announced its earnings results on Thursday, July 30th. The biopharmaceutical company reported $2.04 EPS for the quarter, beating analysts' consensus estimates of $1.60 by $0.44. The firm had revenue of $12.97 billion for the quarter, compared to analysts' expectations of $11.74 billion. Bristol Myers Squibb had a return on equity of 66.90% and a net margin of 18.87%.Bristol Myers Squibb's quarterly revenue was up 5.7% on a year-over-year basis. During the same quarter in the prior year, the firm earned $1.46 EPS. Bristol Myers Squibb has set its FY 2026 guidance at 6.750-7.000 EPS. Equities analysts forecast that Bristol Myers Squibb Company will post 6.95 EPS for the current fiscal year.

Bristol Myers Squibb Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Monday, August 3rd. Investors of record on Thursday, July 2nd were paid a $0.63 dividend. The ex-dividend date of this dividend was Thursday, July 2nd. This represents a $2.52 annualized dividend and a yield of 4.0%. Bristol Myers Squibb's payout ratio is presently 55.51%.

Wall Street Analysts Forecast Growth

A number of research firms have recently issued reports on BMY. Sanford C. Bernstein upgraded shares of Bristol Myers Squibb from a "market perform" rating to an "outperform" rating in a research report on Wednesday, August 5th. JPMorgan Chase & Co. upped their price target on Bristol Myers Squibb from $67.00 to $73.00 and gave the stock an "overweight" rating in a report on Friday, July 31st. Truist Financial reaffirmed a "buy" rating and issued a $70.00 price objective (up from $65.00) on shares of Bristol Myers Squibb in a research note on Friday, July 31st. Cantor Fitzgerald reaffirmed a "neutral" rating and set a $59.00 price objective (up from $54.00) on shares of Bristol Myers Squibb in a report on Friday, July 31st. Finally, Roth Capital began coverage on Bristol Myers Squibb in a research report on Wednesday, August 5th. They set a "buy" rating and a $75.00 target price on the stock. One investment analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating, ten have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $66.33.

Insiders Place Their Bets

In other Bristol Myers Squibb news, SVP Phil M. Holzer sold 500 shares of the company's stock in a transaction dated Tuesday, August 25th. The shares were sold at an average price of $67.50, for a total value of $33,750.00. Following the transaction, the senior vice president directly owned 16,862 shares in the company, valued at approximately $1,138,185. This represents a 2.88% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders own 0.05% of the company's stock.

About Bristol Myers Squibb

Bristol Myers Squibb is a global biopharmaceutical company that discovers, develops and commercializes prescription medicines. Its portfolio includes therapies for cancer, blood disorders, cardiovascular disease, immune-mediated conditions and psychiatric disorders. Key products include Opdivo and Yervoy for oncology, Eliquis for reducing the risk of stroke and systemic embolism, Revlimid for certain blood cancers, and several other specialty medicines.

The company serves patients and healthcare providers in markets around the world, with operations and commercial activities spanning North America, Europe, Asia-Pacific and other international regions.

Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol Myers Squibb Company (NYSE:BMY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.